The impact of COVID-19 on diagnostic biomarkers in neuropsychiatric and neuroimmunological diseases: a review.

Abstract

Coronavirus disease 2019 (COVID-19) is an infectious respiratory disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Evidence-based emerging reports of neurological manifestations show that SARS-CoV-2 can attack the nervous system. However, little is known about the biomarkers in disease in neuropsychiatric and neuroimmunological disorders. One of the important keys in the management of COVID-19 is an accurate diagnosis. Biomarkers could provide valuable information in the early detection of disease etiology, diagnosis, further treatment, and prognosis. Moreover, ongoing investigations on hematologic, biochemical, and immunologic biomarkers in nonsevere, severe, or fatal forms of COVID-19 patients provide an urgent need for the identification of clinical and laboratory predictors. In addition, several cytokines acting through mechanisms to emerge immune response against SARS-CoV-2 infection are known to play a major role in neuroinflammation. Considering the neuroinvasive potential of SARS-CoV-2, which can be capable of triggering a cytokine storm, the current evidence on inflammation in psychiatry and neurodegenerative by emerging neuroinflammation is discussed in this review. We also highlighted the hematologic, biochemical, and immunologic biomarkers in COVID-19 diagnosis. COVID-19 prognostic biomarkers in patients with neuropsychiatric and neuroimmunological diseases are also explained.

• Authors: Masoomeh Dadkhah, Sahand Talei, Donya Doostkamel, Soheila Molaei, Nima Rezaei
• Journal: Reviews in the neurosciences (Rev Neurosci) Vol. 33 Issue 1 Pg. 79-92 (01 27 2022) ISSN: 2191-0200 [Electronic] Germany
• PMID: 34087964 (Publication Type: Journal Article, Review)
• Copyright: © 2021 Walter de Gruyter GmbH, Berlin/Boston.

Chemical References

• Biomarkers

Topics

• Biomarkers
• COVID-19
• COVID-19 Testing
• Humans
• Neuroinflammatory Diseases
• SARS-CoV-2